跳至主要内容
临床试验/NCT00752778
NCT00752778终止4 期

MRI Follow-up of Macrophagic Infiltration in MS Patients Treated With Tysabri

University Hospital, Strasbourg, France6 个研究点 分布在 1 个国家目标入组 8 人开始时间: 2008年12月1日最近更新:
适应症

试验速览

阶段
4 期
状态
终止
发起方
入组人数
8
试验地点
6
主要终点
Number of enhanced lesions on MRI before and after treatment. PET scan modification in brain (in enhanced lesions and in the whole brain).

研究概览

简要总结

To evaluate the diagnosis value of MRI and positon emission tomography (PET) scan for studying macrophagic infiltration and other brain modification in multiple sclerosis (MS) patients treated with Natalizumab (Tysabri).

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients diagnosed with MS
  • Treatment with Tysabri planned

排除标准

  • Allergy to Tysabri or MRI contrast products
  • Pregnancy

结局指标

主要结局

Number of enhanced lesions on MRI before and after treatment. PET scan modification in brain (in enhanced lesions and in the whole brain).

时间窗: At baseline and after 3 months of treatment.

次要结局

  • Correlation with relapses.(During the 3 months of treatment and the 3 following months.)

研究者

发起方
University Hospital, Strasbourg, France
申办方类型
Other
责任方
Sponsor

研究点 (6)

Loading locations...

相似试验